BioSpaceOriginal article
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
Data ReadoutpositiveKyverna CAR TPositive
AI Analysis
Summary
Kyverna Therapeutics reported positive data for its CAR T cell therapy as a potential first-in-class treatment for autoimmune disease, amid ongoing safety concerns following reported deaths in Novartis' autoimmune CAR T trials.
Clinical Trial Data
Outcome Details
Data supporting market approval case for first CAR T in autoimmune disease
Importance:6/10
Sentiment:
0.60
CAR T cell therapyautoimmune diseasesafety concernsregulatory pathwayclinical data
Read the original article
Published by BioSpace on October 5, 2026 4:44 AM